Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Overview
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Companies Involved in Therapeutics Development
Astraea Therapeutics LLC
Grunenthal GmbH
Imbrium Therapeutics LP
Recordati SpA
Trigemi Inc
Tris Pharma Inc
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Drug Profiles
AT-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-403 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cebranopadol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRT-6010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMB-115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Agonize ORL1 for Acute Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REC-0438 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Nociceptin Receptor for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules To Agonize Nociceptin Receptors For Alcohol Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TI-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Dormant Products
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Discontinued Products
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Product Development Milestones
Featured News & Press Releases
Aug 28, 2020: Imbrium Therapeutics presents first data and describes novel mechanism of action for IMB-115, a potential first-in-class treatment for insomnia disorder, at 34th Annual Sleep Meeting
Oct 16, 2019: Imbrium Therapeutics announces first patient dosed in phase 2 study of potential first-in-class molecule for insomnia associated with Alcohol Cessation
Jun 25, 2019: Imbrium Therapeutics advances insomnia pipeline through initiation of a phase 2 study of potential first-in-class molecule for insomnia associated with alcohol cessation
Aug 29, 2018: Scientists take big step toward finding non-addictive pain killer
Sep 30, 2016: Grunenthal’s cebranopadol, a novel strong algesic, meets primary efficacy endpoint in Phase 3 trial in cancer pain
Aug 09, 2016: NIH Grant Will Fund Development of Small Molecules for Post-Traumatic Stress Disorder
May 23, 2016: Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Potential and a Favorable Respiratory Profile
Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Astraea Therapeutics LLC, 2021
Pipeline by Grunenthal GmbH, 2021
Pipeline by Imbrium Therapeutics LP, 2021
Pipeline by Recordati SpA, 2021
Pipeline by Trigemina Inc, 2021
Pipeline by Tris Pharma Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021